[go: up one dir, main page]

AR083003A1 - Lactamas sustituidas por piperidinilo como moduladores de gpr119 - Google Patents

Lactamas sustituidas por piperidinilo como moduladores de gpr119

Info

Publication number
AR083003A1
AR083003A1 ARP110103373A ARP110103373A AR083003A1 AR 083003 A1 AR083003 A1 AR 083003A1 AR P110103373 A ARP110103373 A AR P110103373A AR P110103373 A ARP110103373 A AR P110103373A AR 083003 A1 AR083003 A1 AR 083003A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkoxy
halogen
independently selected
Prior art date
Application number
ARP110103373A
Other languages
English (en)
Inventor
Steven Armen Boyd
John P Fischer
Ronald Jay Hinklin
Scott Alan Pratt
Kevin Ronald Condroski
Jay Bradford Fell
Thomas Daniel Aicher
Ajay Singh
Timothy M Turner
Josef Roland Bencsik
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR083003A1 publication Critical patent/AR083003A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Son moduladores de GPR119 y son útiles en el tratamiento o prevención de enfermedades tales como pero sin limitación a, diabetes tipo 2, complicaciones diabéticas, síntomas de diabetes, síndrome metabólico, obesidad, dislipidemia y afecciones relacionadas.Reivindicación 1: Un compuesto que tiene la fórmula general (1) o una sal farmacéuticamente aceptable del mismo, donde: L es O ó NRx; Rx es H o alquilo C1-3; X1 es N o CR1 y X2 es N o CR2, donde solo uno de X1 y X2 puede ser N; R1, R2, R3 y R4 se seleccionan independientemente de H, halógeno, CF3, alquilo C1-6 y alcoxi C1-6; R5 es (alquil C1-3)sulfonilo, (cicloalquil C3-6)sulfonilo, (ciclopropilmetil)sulfonilo, fenilsulfonilo, CN, Br, CF3 o tetrazolilo opcionalmente sustituido por alquilo C1-3; R7 se selecciona de los compuestos de fórmula (2) ó (3); R8 es alquilo C1-6, fluoroalquilo C1-6, difluoroalquilo C1-6, trifluoroalquilo C1-6, tricloroalquilo C1-6, Cyc1, Ar1, hetCyc1 o hetAr1; Cyc1 es cicloalquilo C3-6 opcionalmente sustituido por CF3; Ar1 es fenilo opcionalmente sustituido por uno o más grupos seleccionados independientemente de halógeno, CF3, alquilo C1-4 y alcoxi C1-4; hetCyc1 es un heterociclo de 5 - 6 miembros que tienen un átomo de nitrógeno en el anillo y que está opcionalmente sustituido por uno o más grupos seleccionados independientemente de halógeno, CF3, alquilo C1-4 y alcoxi C1-4; hetAr1 es un heteroarilo de 6 miembros que tiene un átomo de nitrógeno en el anillo y que está opcionalmente sustituido con uno o más grupos seleccionados independientemente de halógeno, CF3, alquilo C1-6 y alcoxi C1-4; y n es 1, 2 ó 3.
ARP110103373A 2010-09-17 2011-09-16 Lactamas sustituidas por piperidinilo como moduladores de gpr119 AR083003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38379910P 2010-09-17 2010-09-17

Publications (1)

Publication Number Publication Date
AR083003A1 true AR083003A1 (es) 2013-01-23

Family

ID=44736053

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103373A AR083003A1 (es) 2010-09-17 2011-09-16 Lactamas sustituidas por piperidinilo como moduladores de gpr119

Country Status (19)

Country Link
US (1) US20130184257A1 (es)
EP (1) EP2616074A1 (es)
JP (1) JP2013537234A (es)
KR (1) KR20130099970A (es)
CN (1) CN103221046A (es)
AR (1) AR083003A1 (es)
AU (1) AU2011301934A1 (es)
BR (1) BR112013006344A2 (es)
CA (1) CA2811525A1 (es)
CL (1) CL2013000714A1 (es)
CR (1) CR20130173A (es)
IL (1) IL225214A0 (es)
MX (1) MX2013003034A (es)
PH (1) PH12013500472A1 (es)
RU (1) RU2013117403A (es)
SG (1) SG188985A1 (es)
TW (1) TW201213322A (es)
UY (1) UY33614A (es)
WO (1) WO2012037393A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130113948A (ko) 2010-05-17 2013-10-16 어레이 바이오파마 인크. Gpr119 조절제로서의 피페리디닐-치환된 락탐류
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
IN2014KN01075A (es) 2011-11-18 2015-10-09 Heptares Therapeutics Ltd
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
KR20160132887A (ko) 2014-04-04 2016-11-21 사노피 당뇨, 비만, 이상지질혈증 및 관련 장애 치료를 위한 gpr119 조절자로서의 치환된 인다논 화합물
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CN104892517A (zh) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 酰肼类化合物、其制备方法及用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104672116B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含苯磺酰肼和腈基苯结构gpr119激动剂及其用途
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018153849A1 (en) 2017-02-21 2018-08-30 Sanofi Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN115667277A (zh) 2020-02-28 2023-01-31 卡尔优普公司 Gpr40激动剂
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AU2007291252A1 (en) * 2006-08-30 2008-03-06 Inovacia Ab Pyridine compounds for treating GPR119 related disorders
CN102089301A (zh) * 2008-07-10 2011-06-08 普洛希典有限公司 哌啶gpcr激动剂

Also Published As

Publication number Publication date
UY33614A (es) 2013-04-05
CL2013000714A1 (es) 2013-10-11
EP2616074A1 (en) 2013-07-24
AU2011301934A1 (en) 2013-05-16
RU2013117403A (ru) 2014-10-27
CN103221046A (zh) 2013-07-24
IL225214A0 (en) 2013-06-27
MX2013003034A (es) 2013-08-15
CA2811525A1 (en) 2012-03-22
BR112013006344A2 (pt) 2016-06-21
SG188985A1 (en) 2013-05-31
JP2013537234A (ja) 2013-09-30
WO2012037393A1 (en) 2012-03-22
KR20130099970A (ko) 2013-09-06
TW201213322A (en) 2012-04-01
CR20130173A (es) 2013-05-15
PH12013500472A1 (en) 2013-04-29
US20130184257A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
AR083003A1 (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
AR081197A1 (es) Lactamas sustituidas con piperidinil o como moduladores de gpr 119
AR081369A1 (es) Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX359651B (es) Antagonistas de cxcr7.
CO6321238A2 (es) Compuesto heterociclico con accion antagonista del glucagon
AR090928A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina heterociclicos sustituidos
CR20140143A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UA110471C2 (ru) 5-алкінілпіримідини
AR088638A1 (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
CO6561783A2 (es) Inhibidores del virus flaviviridae
AR092827A1 (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR093825A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR088857A1 (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas
CO6801734A2 (es) Derivados de etinilo como moduladores alostéricos positivos de mglur5
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR077642A1 (es) Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
GT201300085A (es) Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida
ECSP13012980A (es) Derivados de fenil- o piridinil-etinilo
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
CL2020002588A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016)
CR20130476A (es) Derivados de pirazolidin-3-ona
DOP2015000132A (es) Moduladores selectivos del receptor de andrógenos novedosos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal